Homburger successfully enforces Novartis' deferasirox patents before the Swiss Federal Patent Court
On December 15, 2021, the Swiss Federal Patent Court handed down a preliminary injunction judgment prohibiting Mepha Pharma AG from marketing a generic version of Novartis’ drug Jadenu® in Switzerland. The Federal Patent Court considers it established on a prima facie basis that the generic product infringes two Novartis patents. Defendant may appeal the judgment to the Swiss Federal Supreme Court.
The Homburger team was led by partner Andri Hess and included associate Angelika Murer (both IP/IT, Litigation).